Alvotech fails pre-approval inspection for its proposed Humira interchangeable biosimilar

Almost a dozen new Humira biosimilars will finally launch in the US next year, beginning with Amgen’s in January (almost four years behind Europe), but one of the top follow-on contenders, with a higher concentration version and a potential interchangeable designation to boot, has now been stalled due to manufacturing...

Click to view original post